Abstract:Background Excessive generation of reactive oxygen species (ROS) in the presence of a defective antioxidant system can induce cellular damage and disrupt normal physiological functions. Several studies have revealed the unfavorable role of ROS in promoting the growth, proliferation, migration, and survival of leukemia cells. In this review study, we summarize the mechanisms of ROS production and its role in leukemogenesis, counteractive effects of antioxidants, and implicate the current ROS-dependent anticancer therapies in acute myeloid leukemia. Body The dysregulation of the redox system is known to play a significant role in the pathogenesis of leukemia. Leukemia cells generate high levels of ROS, which further increases the levels through extra pathways, including mitochondrial deoxyribonucleic mutation, leukemic oncogene activation, increased nicotinamide adenine phosphate hydrogen (NADPH), and cytochrome P450 activities. Aforementioned pathways once activated have shown to promote genomic instability, induce drug resistance to leukemia medical therapy, disease relapse and reduce survival period. The current standard of treatment with chemotherapy employs the pro-oxidant approach to induce apoptosis and promote tumor regression. However, this approach retains several deleterious effects on the subject resulting in degradation of the quality of life. Nevertheless, the addition of an antioxidant as an adjuvant drug to chemotherapy alleviates treatment-related toxicity, increases chemotherapeutic efficacy, and improves survival rates of a patient. Conclusion Acute myeloid leukemia remains a daunting challenge to clinicians. The desire to achieve the maximum benefit of chemotherapy but also improve patient outcomes is investigated. ROS generated through several pathways promotes leukemogenesis, drug resistance, and disease relapse. Chemotherapy, the mainstay of treatment, further upregulates ROS levels. Therefore, the addition of an antioxidant to leukemia medical therapy alleviates toxicity and improves patient outcomes.

Targeting peroxiredoxins against leukemia.

Adenanthin Targets Peroxiredoxin I and II to Induce Differentiation of Leukemic Cells.

Targeting Redox Regulation as a Therapeutic Opportunity against Acute Leukemia: Pro-Oxidant Strategy or Antioxidant Approach?

Identification of H7 As a Novel Peroxiredoxin I Inhibitor to Induce Differentiation of Leukemia Cells.

Overview of thioredoxin system and targeted therapies for acute leukemia

New insights into the roles of peroxiredoxins in cancer

Synthesis and Molecular Recognition Studies on Small-Molecule Inhibitors for Thioredoxin Reductase

Targeting ROS in cancer: rationale and strategies

Adenanthin targets peroxiredoxin I|[sol]|II to kill hepatocellular carcinoma cells

Targeting Ferroptosis for Cancer Therapy: Exploring Novel Strategies from Its Mechanisms and Role in Cancers

Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells

MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.

Regulation of Leukemogenesis Via Redox Metabolism

Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia.

The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications

Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression

Dual Role of PRDX1 in Redox-Regulation and Tumorigenesis: Past and Future.

Redox, cysteines, and kinases—A triad sustaining myeloid leukemia

Targeting the Thioredoxin System for Cancer Therapy.

Targeting the Redox Landscape in Cancer Therapy

Reactive oxygen species in eradicating acute myeloid leukemic stem cells.